Stryker (SYK) Competitors

Cardinal Health has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, Stryker has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

87.2% of Cardinal Health shares are held by institutional investors. Comparatively, 77.1% of Stryker shares are held by institutional investors. 0.1% of Cardinal Health shares are held by insiders. Comparatively, 4.6% of Stryker shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Cardinal Health presently has a consensus target price of $266.56, indicating a potential upside of 19.10%. Stryker has a consensus target price of $374.42, indicating a potential upside of 34.07%. Given Stryker's higher probable upside, analysts plainly believe Stryker is more favorable than Cardinal Health.

Stryker has a net margin of 14.43% compared to Cardinal Health's net margin of 0.67%. Stryker's return on equity of 23.63% beat Cardinal Health's return on equity.

Stryker has lower revenue, but higher earnings than Cardinal Health. Stryker is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks.

Cardinal Health pays an annual dividend of $2.06 per share and has a dividend yield of 0.9%. Stryker pays an annual dividend of $3.52 per share and has a dividend yield of 1.3%. Cardinal Health pays out 28.5% of its earnings in the form of a dividend. Stryker pays out 36.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Cardinal Health has raised its dividend for 29 consecutive years and Stryker has raised its dividend for 32 consecutive years. Stryker is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Cardinal Health and Cardinal Health both had 10 articles in the media. Stryker's average media sentiment score of 0.69 beat Cardinal Health's score of 0.64 indicating that Stryker is being referred to more favorably in the news media.

In the previous week, Stryker had 5 more articles in the media than Cencora. MarketBeat recorded 10 mentions for Stryker and 5 mentions for Cencora. Stryker's average media sentiment score of 0.69 beat Cencora's score of 0.61 indicating that Stryker is being referred to more favorably in the media.

77.1% of Stryker shares are owned by institutional investors. Comparatively, 97.5% of Cencora shares are owned by institutional investors. 4.6% of Stryker shares are owned by company insiders. Comparatively, 0.4% of Cencora shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Stryker has higher earnings, but lower revenue than Cencora. Cencora is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Stryker has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, Cencora has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market.

Stryker pays an annual dividend of $3.52 per share and has a dividend yield of 1.3%. Cencora pays an annual dividend of $2.40 per share and has a dividend yield of 0.8%. Stryker pays out 36.5% of its earnings in the form of a dividend. Cencora pays out 17.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has raised its dividend for 32 consecutive years and Cencora has raised its dividend for 15 consecutive years. Stryker is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Stryker currently has a consensus target price of $374.42, suggesting a potential upside of 34.07%. Cencora has a consensus target price of $370.85, suggesting a potential upside of 20.77%. Given Stryker's higher possible upside, equities research analysts plainly believe Stryker is more favorable than Cencora.

Stryker has a net margin of 14.43% compared to Cencora's net margin of 0.79%. Cencora's return on equity of 125.45% beat Stryker's return on equity.

Stryker has higher revenue and earnings than DaVita. DaVita is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

DaVita presently has a consensus price target of $233.43, suggesting a potential upside of 33.39%. Stryker has a consensus price target of $374.42, suggesting a potential upside of 34.07%. Given Stryker's stronger consensus rating and higher probable upside, analysts plainly believe Stryker is more favorable than DaVita.

DaVita has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, Stryker has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market.

90.1% of DaVita shares are held by institutional investors. Comparatively, 77.1% of Stryker shares are held by institutional investors. 1.9% of DaVita shares are held by insiders. Comparatively, 4.6% of Stryker shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Stryker has a net margin of 14.43% compared to DaVita's net margin of 6.05%. Stryker's return on equity of 23.63% beat DaVita's return on equity.

In the previous week, Stryker had 6 more articles in the media than DaVita. MarketBeat recorded 10 mentions for Stryker and 4 mentions for DaVita. Stryker's average media sentiment score of 0.69 beat DaVita's score of 0.00 indicating that Stryker is being referred to more favorably in the news media.

Stryker has a net margin of 14.43% compared to Medtronic's net margin of 13.93%. Stryker's return on equity of 23.63% beat Medtronic's return on equity.

In the previous week, Medtronic had 24 more articles in the media than Stryker. MarketBeat recorded 34 mentions for Medtronic and 10 mentions for Stryker. Medtronic's average media sentiment score of 0.87 beat Stryker's score of 0.69 indicating that Medtronic is being referred to more favorably in the media.

Medtronic pays an annual dividend of $2.88 per share and has a dividend yield of 3.3%. Stryker pays an annual dividend of $3.52 per share and has a dividend yield of 1.3%. Medtronic pays out 70.9% of its earnings in the form of a dividend. Stryker pays out 36.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Medtronic has increased its dividend for 49 consecutive years and Stryker has increased its dividend for 32 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Medtronic has higher revenue and earnings than Stryker. Medtronic is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Medtronic currently has a consensus price target of $103.92, indicating a potential upside of 19.22%. Stryker has a consensus price target of $374.42, indicating a potential upside of 34.07%. Given Stryker's stronger consensus rating and higher possible upside, analysts clearly believe Stryker is more favorable than Medtronic.

Medtronic has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, Stryker has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

82.1% of Medtronic shares are held by institutional investors. Comparatively, 77.1% of Stryker shares are held by institutional investors. 0.3% of Medtronic shares are held by company insiders. Comparatively, 4.6% of Stryker shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.